Enhanced radioiodine uptake in a patient with poorly differentiated papillary thyroid cancer after treatment with rosiglitazone

Clinical Nuclear Medicine

Volumn 31, Issue 9, 2006, Pages 517-519

  Elias, Alan N ^a   Lizotte, Paul ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Differentiation therapy; PPAR; Rosiglitazone; Thyroid cancer

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; IODINE 131; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; ROSIGLITAZONE; THYROGLOBULIN;

ADULT; ARTICLE; CARCINOMA; CASE REPORT; DRUG EFFECT; DRUG EFFICACY; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; LIVER DYSFUNCTION; OUTCOME ASSESSMENT; POORLY DIFFERENTIATED CARCINOMA; THYROGLOBULIN BLOOD LEVEL; THYROID PAPILLARY CARCINOMA;

CELL DIFFERENTIATION; FEMALE; HUMANS; HYPOGLYCEMIA; IODINE RADIOISOTOPES; MIDDLE AGED; NEOPLASM METASTASIS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RADIONUCLIDE IMAGING; THIAZOLIDINEDIONES; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 33747586309     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000233148.45744.44     Document Type: Article

References (27)

1. Roldan Schilling V, Fernandez Abellan P, Dominguez Escribano JR, et al. Acute leukemias after treatment with radioiodine for thyroid cancer. Haematologica. 1998;83:767-768.
2. Wang KL, Lin LY, Chen PM, et al. Chronic myeloid leukemia after treatment with 131 for thyroid carcinoma. Journal of the Chinese Medical Association. 2005;68:230-233.
3. Simon D, Korber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging. 2002;29:775-782.
4. Coelho SM, Corbo R, Buescu A, et al. Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J Endocrinol Invest. 2004;27:334-339.
5. Haugen BR. Redifferentiation therapy in advanced thyroid cancer. Curr Drug Targets Immune Endocr Metabol Disord. 2004;4:175-180.
6. Short SC, Suovuori A, Cook G, et al. A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin Oncol (R Coll Radiol). 2004;16:569-574.
7. Klopper JP, Hays WR, Sharma V, et al. Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther. 2004;3:1011-1020.
8. Tontonoz P, Nagy L, Alvarez JG, et al. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241-252.
9. Welch JS, Ricote M, Akiyama TE, et al. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci U S A. 2003;100:6712-6717.
10. Li AC, Binder CJ, Gutierrez A, et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin. 2004;114:1564-1576.
11. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7:53-58.
12. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall. Zeitschrift fur Kardiologie. 2001;90(suppl 3):125-132.
13. Shen WT, Chung WY. Treatment of thyroid cancer with histone deacetylase inhibitors and peroxisome proliferator-activated receptor-gamma agonists. Thyroid. 2005;15:594-599.
14. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 2004;5:419-429.
15. Park JW, Zarnegar R, Kanauchi H, et al. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid. 2005;15:222-231.
16. Philips JC, Petite C, Willi JP, et al. Effect of peroxisome proliferatoractivated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers. Nucl Med Commun. 2004;25:1183-1186.
17. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci. 2004;25:331-336.
18. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROACTIVE Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
19. Chawla A, Repa JJ, Evans RM, et al. Nuclear receptors and lipid physiology: opening the X-files. Science. 2001;294:1866-1870.
20. Fenner MH, Elstner E. Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. Exp Opin Invest. 2005;14:557-568.
21. Valentiner U, Carlsson M, Erttmann R, et al. Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro. Toxicology. 2005;213:157-168.
22. Li M, Lee TW, Mok TS, et al. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. J Cell. 2005;96:760-774.
23. Hafner C, Reichle A, Vogt T. New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARgamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy. Curr Cancer Drug Targets. 2005;5:393-419.
24. Harris G, Ghazallah RA, Nascene D, et al. PPAR activation and decreased proliferation in oral carcinoma cells with 4-HPR. Otolaryngol Head Neck Surg. 2005;133:695-701.
25. Yu J, Qiao L, Zimmermann L, et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology. 2006;43:134-143.
26. Frohlich E, Machicao F, Wahl R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer. 2005;12:291-303.
27. Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998;273:25573-25580.